news

New innovation centre for biopharma technologies opens

10
SHARES

A facility has opened in Ireland which will allow the biopharma industry to trial and simulate the latest bioprocessing and quality control technologies in a GMP environment.

Pharmaceutical factory worker

A new Innovation Centre has been opened in Dublin, Ireland, by the National Institute for Bioprocessing Research and Training (NIBRT) and Boston Consulting Group (BCG) as part of the Biopharma 4.0 (B4.0) Alliance. 

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The facility will be dedicated to biopharma operations and showcase the latest Industry 4.0 (I4.0) technologies in biopharma manufacturing, bioprocessing, quality control and training. According to the NIBRT, the technologies are integrated with core operating processes to enable proof-of-concept use cases on new discoveries and ways of working, situated in a good manufacturing practice (GMP) simulated environment.

The organisation says that implementing these methodologies in the biopharma and bioprocessing industries could lead to productivity improvements of up to 40 percent. Whilst Europe has typically been a leader in biopharma innovation, as a whole it is behind others and the adoption of next generation technologies is key to maintaining this advantage, says the NIBRT. 

The centre allows visitors and members to sample I4.0 technology demonstrated in a GMP environment and also allows companies to co-create or pilot digital solutions to their specific challenges.

…implementing these methodologies in the biopharma and bioprocessing industries could lead to productivity improvements”

“Biopharma has traditionally lagged behind other industries in the adoption of cutting edge technologies and the B4.0 Alliance identified that a key barrier to this was the provision of a safe GMP space to learn about, experience and co-create digital use-cases as well as understand regulatory perspectives,” says Frank Cordes, Managing Director and Partner at BCG.  “We therefore hope this Centre will encourage companies to experiment with new technologies and develop talent, ensuring the industry can leverage the value from I4.0.”

Share via
Share via